This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis From Phase 3 Study
In a press release early this morning, Pfizer and BioNTech accounced the results of their vaccine candidate against SARS-CoV-2 in the first interim efficacy analysis of its Phase 3 clinical study.
This vaccine candiate, BNT162b2, was found to be more than 90% effective in preventing COVID-19 in 94 participants without evidence of prior SARS-CoV-2 infection.